Findings

What do systematic reviews say?

2 questions · 2 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 100%High 0 · 0%

Sclerotherapy (polidocanol) vs sclerotherapy (any sclerosant)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.94 [0.62, 1.43]
6 studies · 819 participants
Moderate

Sclerotherapy (hypertonic glucose plus polidocanol) vs sclerotherapy (hypertonic glucose)

Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins

Sclerotherapy (hypertonic glucose plus polidocanol) showed no clear difference in adverse events ‐ hyperpigmentation ( compared with sclerotherapy (hypertonic glucose) (moderate certainty).

1 finding from 1 review

Treatment for telangiectasias and reticular veins 2021 · Cochrane Headline outcomes only
RR 0.79 [0.62, 1.01]
2 studies · 191 participants
Moderate